Co-administration with CYP3A inhibitors (moderate and strong) results in increased systemic exposure to amlodipine and may require dose reduction. Monitor for symptoms ofhypotensionand edema when amlodipine is co-administered with CYP3A inhibitors to determine the need for dose adjustment [seeCLINICAL PHA...
Co-administration with CYP3A inhibitors (moderate and strong) results in increased systemic exposure to amlodipine and may require dose reduction. Monitor for symptoms ofhypotensionand edema when amlodipine is co-administered with CYP3A inhibitors to determine the need for dose adjustment [seeCLINICAL PHA...
The limit of quantification is low enough to monitor at least five half-lives of AML, VAL and HCTZ concentration with good intra- and inter-assay reproducibility (% CV) for the quality controls. The linear dynamic range established was adequate to measure the plasma concentration of AML, VAL ...